Influenza HA (518-526) 

Influenza HA (518-526) is an H-2d-restricted CTL epitope derived from influenza virus hemagglutinin. Influenza HA (518-526) is highly conserved across various H5N1, some H9N2, and H1N1 strains. Influenza HA (518-526) binds to the mouse MHC class I allele K^d to form a complex, which is then recognized by specific CD8⁺ T cells. Influenza HA (518-526) is an immunodominant epitope in influenza-infected BALB/c mice, and it stimulates CD8⁺ T cells to secrete IFN-γ to induce a robust immune response. Currently, Influenza HA (518-526) is widely used in research related to respiratory syncytial virus (RSV), influenza virus, and H5N1 influenza^[1][2][3].

Influenza HA (518-526) (3 hours) incorporation into the neuraminidase stalk of PR8 influenza virus reduces the enzyme's specific activity to 15% of wild-type levels in purified virus preparations^[1].
Influenza HA (518-526) (0.001 multiplicity of infection; 0-48 hours post-infection) incorporation into the neuraminidase stalk of PR8 influenza virus does not alter the virus's in vitro growth kinetics in MDCK cells^[1].
Influenza HA (518-526) (72 hours) incorporation into the neuraminidase stalk of PR8 influenza virus does not change the virus's plaque size in MDCK cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

940.05

C₄₂H₆₉N₉O₁₅

186302-15-8

Solid

White to off-white

Ile-Tyr-Ser-Thr-Val-Ala-Ser-Ser-Leu

IYSTVASSL

Room temperature in continental US; may vary elsewhere.

Sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

• [1]. De Baets S, et al. Recombinant influenza virus carrying the respiratory syncytial virus (RSV) F85-93 CTL epitope reduces RSV replication in mice. J Virol. 2013;87(6):3314-3323.  [Content Brief]

  [2]. Jiang J, et al. Enhancement of virus-specific expansion of transgenic CD8 T cells in aged mice by dendritic cells. Mech Ageing Dev. 2010;131(9):580-583.

  [3]. Hoelscher MA, et al. Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice. Lancet. 2006;367(9509):475-481.